BridgeBio Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
BridgeBio Pharma Inc. (BBIO) Misses Q4 EPS by 7c
February 23, 2023 7:43 AM ESTBridgeBio Pharma Inc. (NASDAQ: BBIO) reported Q4 EPS of ($0.92), $0.07 worse than the analyst estimate of ($0.85). Revenue for the quarter came in at $1.87 million versus the consensus estimate of $5.01 million.
For earnings history and earnings-related data on BridgeBio Pharma Inc. (BBIO) click here.
... More